Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyViva Health Nucala (mepolizumab) Prior Auth | Open…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-P0260

    Nucala (mepolizumab) prior authorization and coverage criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-P0260 alerts

    Get alerted when Policy IC-P0260 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy describes prior authorization, dosing limits, initial and renewal clinical criteria, and concomitant therapy restrictions for coverage of subcutaneous mepolizumab (Nucala) for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyNucala (mepolizumab) prior authorization and coverage criteria
    Policy CodePolicy IC-P0260
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionPrior authorization is required; initial authorization is valid for 12 months and may be renewed every 12 months thereafter.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsinitial authorization duration
    100max units (asthma/COPD/CRSwNP)
    300max units (EGPA/HES)
    >=150asthma eosinophil threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=300
    COPD eosinophil threshold
    ~100+contraindicated concomitant agents (approx.)

    Coverage and Medical Necessity Criteria

    Initial Approval Criteria

    Target agent(s) will be approved when ALL of the following are met:

    Initial overall

    • Continuation of therapy or new request: Either continuation of therapy within past 90 days OR meet new-request diagnostic/treatment criteria

      Continuation includes prior use within 90 days or prescriber attestation of recent use and risk if changed

    • Severe eosinophilic asthma criteria

      • Diagnostic confirmation: One of: baseline blood eosinophils >=150 cells/microliter; FeNO >=20 ppb while on high-dose ICS or daily OCS; sputum eosinophils >=2% while on high-dose ICS or daily OCS; or systemic corticosteroid dependence
      • Uncontrolled disease or prior biologic: One of: >=2 severe exacerbations requiring systemic steroid in past 12 months; >=1 serious exacerbation requiring hospitalization/ventilation/ED/UC in past 12 months; controlled asthma that worsens with steroid taper; baseline FEV1 <80% predicted; OR prior use of an FDA‑labeled/compendia‑supported biologic in past 12 months
      • Concomitant controller therapy and specialist: Member must be on/continue controller therapy (e.g., maximally tolerated inhaled corticosteroid for >=3 months with 90 days adherence plus LABA/LAMA as applicable) and prescriber is a relevant specialist or has consulted one
    • COPD criteria

      • Diagnosis confirmation: Spirometry with post‑bronchodilator FEV1/FVC <0.7
      • Eosinophilic phenotype: Baseline blood eosinophils >=300 cells/microliter
      • Inadequate control or prior biologic: One of: >=2 moderate COPD exacerbations in past 12 months; >=1 severe COPD exacerbation requiring hospitalization/observation >24 hrs in past 12 months; OR prior biologic use for COPD in past 12 months
      • Treatment trials and continuation: Member must have trials/adherence to ICS and LAMA/LABA (or triple therapy as appropriate) for >=3 months with 90 days adherence and will continue COPD inhaled maintenance therapy with the agent
    • EGPA criteria

      • Eosinophil threshold: Baseline blood eosinophils >=1000 cells/microliter OR >=10% on WBC differential
      • Asthma and non‑severe disease: Member has history/presence of asthma AND does NOT have organ‑ or life‑threatening manifestations (e.g., alveolar hemorrhage, glomerulonephritis, CNS vasculitis, cardiac involvement)
      • OCS use: Either currently treated with OCS >=4 weeks within past 90 days and will use OCS with the agent, OR intolerance to one OCS, OR contraindication to all OCS
      • Indication usage: Agent will be used for relapsing/refractory disease or maintenance of remission
    • HES criteria

      • Duration and eosinophils: Diagnosis for >=6 months AND baseline blood eosinophils >=1000 cells/microliter
      • Organ evaluation and exclusions: Evaluation of organ involvement performed AND no identifiable non‑hematologic secondary (reactive) cause AND FIP1L1‑PDGFRA negative
      • Disease activity or prior therapy failure: At least 2 HES flares in past 12 months OR active signs/symptoms AND tried and had inadequate response to one of: OCS, hydroxyurea, interferon‑alfa, or immunosuppressive agent; or corticosteroid‑dependent; or intolerance/contraindication to listed agents
      • Concurrent therapy: Member will continue existing HES therapy (e.g., OCS, hydroxyurea, interferon‑alfa, cyclosporine, methotrexate) in combination with the agent
    • CRSwNP criteria

      • Symptom requirement: At least TWO CRS symptoms: nasal discharge, nasal obstruction, hyposmia, facial pressure/pain
      • Duration and confirmation: Symptoms for >=12 consecutive weeks AND diagnosis confirmed by anterior rhinoscopy, nasal endoscopy, or CT of sinuses
      • Intranasal steroid trial: Tried and had inadequate response to one intranasal corticosteroid for >=4 weeks OR intolerance to one intranasal corticosteroid OR contraindication to all intranasal corticosteroids
      • Maintenance therapy: Member is currently treated with and will continue standard nasal polyp maintenance therapy in combination with the agent
    • General requirements: Prescriber is a specialist in the member's diagnosis area or has consulted one; agent will not be used with contraindicated immunomodulators unless prescribing information permits and supporting evidence is provided; no FDA‑labeled contraindications to the agent

      Compendia allowed: AHFS, DrugDex 1 or 2a, or NCCN 1 or 2a

    Renewal Criteria

    Target Agent(s) will be approved when ALL of the following are met:

    Renewal overall

    • Prior approval: Member was previously approved through the plan's prior authorization process
    • Clinical benefit: Member has had clinical benefit with the requested agent
    • Ongoing adherence and concomitant therapy: If asthma/COPD/CRSwNP, member remains on and adherent to required control/maintenance therapies within past 90 days; prescriber is a relevant specialist or consulted one
    • Concomitant immunomodulator use: Either member is NOT using the agent with another immunomodulatory agent OR if used in combination, prescribing information must not limit use and supporting evidence must be submitted

    Renewal contraindicated with listed concomitant therapies

    Renewal is contraindicated when ANY of the following concomitant therapies are present

    Concomitant therapy contraindications: Presence of concurrent therapy with any medication named in the renewal section (examples include adalimumab products, dupilumab, benralizumab, reslizumab, infliximab and many other biologic/immunomodulatory agents).any single listed agent

    The policy lists a long roster of specific products by brand and generic names across chunks 18–37.

    Renewal: Prohibited Concomitant Therapies

    Renewal is subject to confirmation that NONE of the following concomitant therapies are being used:

    Contraindicated Concomitant Therapies: Member must NOT be receiving any agent listed as 'Contraindicated as Concomitant Therapy' with Nucala (examples repeatedly listed include: adalimumab products [Humira, Hadlima, Hulio, Hyrimoz, Idacio], infliximab/Inflectra, benralizumab (Fasenra), sarilumab (Kevzara), anakinra (Kineret), depemokimab (Exdensur), tildrakizumab (Ilumya), ustekinumab (Imuldosa), canakinumab (Ilaris), deuruxolitinib (Leqselvi), ritlecitinib (Litfulo), nemolizumab (Nemluvio), baricitinib (Olumiant), and many other named biologic or immunomodulatory agents).none

    The policy text repeats the list across multiple lines; renewal requires absence of these therapies.

    Renewal and Dosing Criteria

    Policy renewal and dosing guidance (extracted items present in this portion):

    Contraindicated Concomitant Therapy: Member must not be receiving any medication listed under 'Contraindicated as Concomitant Therapy' (extensive list of biologics, JAK inhibitors, and other immunomodulators).absent

    Multiple pages repeat the contraindicated list.

    Dosing per Indication: Dosing must match labeled indication: Pediatrics 6-11 years severe eosinophilic asthma = 40 mg SC q4w; Adults/adolescents >=12 years severe eosinophilic asthma and COPD = 100 mg SC q4w; EGPA = 100 mg SC q4w or 300 mg SC q4w as three 100 mg injections; HES = 300 mg SC q4w as three 100 mg injections; CRSwNP = 100 mg SC q4w.per indication

    Administer separate injections at least 2 inches apart when multiple injections required.

    Covered Diagnoses

    Covered diagnoses (policy requires diagnosis matching one of the listed codes):

    Covered diagnosis codes: Member must have a diagnosis that matches one of the ICD-10 codes listed in Appendix 1

    See Appendix 1 for full code list

    For hypereosinophilic syndrome (HES) the policy requires that the member does NOT have an identifiable non-hematologic secondary (reactive) cause of HES (examples include infection, allergy/atopy, autoimmune disease, drug reaction, metabolic condition, solid tumor/lymphoma) and does NOT have FIP1L1-PDGFRA-positive disease. These exclusion conditions are part of the HES-specific initial approval criteria and must be documented prior to approval.

    Within the extracted renewal material there are no explicit clinical exclusions by diagnosis beyond the listed medication prohibitions. The renewal criteria are presented primarily as a prohibition of specific concomitant therapies rather than additional diagnosis-based exclusions.

    Renewal requires that the member is not receiving concomitant treatment with the numerous biologic and immunomodulatory agents enumerated in the policy. Examples repeatedly listed in the renewal section include adalimumab products (Humira, Hadlima, Hulio, Hyrimoz, Idacio), infliximab/Inflectra/Remicade, benralizumab (Fasenra), sarilumab (Kevzara), anakinra (Kineret), deuruxolitinib (Leqselvi), ritlecitinib (Litfulo), and nemolizumab (Nemluvio) among many others listed across the renewal tables.

    The policy explicitly states that concurrent use with any medication listed under the heading "Contraindicated as Concomitant Therapy" is not allowed. The renewal criteria present an extensive list (e.g., apremilast, ustekinumab products, multiple infliximab and rituximab formulations, JAK inhibitors such as tofacitinib/Xeljanz and upadacitinib/Rinvoq, tezepelumab, omalizumab, and many others) which are identified as contraindicated when used concomitantly with mepolizumab for the purpose of renewal consideration.

    For Medicare members, applicable Medicare coverage rules apply: providers must follow Medicare Benefit Policy guidance and any relevant National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), or Local Coverage Articles (LCAs). The policy notes that Medicare-specific determinations may exist and compliance with those documents is required where applicable.

    Use of mepolizumab is not permitted when the member has any FDA-labeled contraindication to the agent. The policy requires that the member does NOT have any FDA-labeled contraindications as a condition of approval or renewal.

    The policy specifies that renewal will be considered not medically necessary if the member is concurrently receiving one or more agents listed as "Contraindicated as Concomitant Therapy". Documentation at renewal must confirm the absence of these concomitant agents; presence of any listed contraindicated medication may render renewal not medically necessary.

    Consistent with the renewal rules, the policy states that concurrent use of mepolizumab with medications listed as contraindicated would render the requested therapy inappropriate. The extensive enumerated list of biologics, JAK inhibitors, and other immunomodulators in the renewal section is cited as making concurrent therapy contraindicated for renewal or ongoing coverage.

    Billing, Dosing Limits, and Codes

    Dosing limits - common indicationsHCPCSCovered
    HCPCS units: 100/28 daysMax billable units per 28 days for COPD, CRSwNP, Severe Eosinophilic Asthma
    Dosing limits - EGPA and HESHCPCSCovered
    HCPCS units: 300/28 daysMax billable units per 28 days for EGPA, HES
    HCPCS CodesHCPCSCovered
    J2182Injection, mepolizumab, 1 mg; 1 billable unit = 1 mg
    NDCsNDC
    00173-0881-xxNucala 100 mg/mL lyophilized powder single-dose vial
    00173-0892-xxNucala 100 mg/mL single-dose prefilled autoinjector or syringe (cartons of 1)
    00173-0904-xxNucala 40 mg/0.4 mL single-dose prefilled syringe (cartons of 1)
    NDCsNDC
    00173-0881-xxNucala 100 mg/mL lyophilized powder single-dose vial
    00173-0892-xxNucala 100 mg/mL single-dose prefilled autoinjector or syringe (cartons of 1)
    00173-0904-xxNucala 40 mg/0.4 mL single-dose prefilled syringe (cartons of 1)
    Covered ICD-10 Diagnosis CodesICD-10Covered
    D72.110Idiopathic hypereosinophilic syndrome [IHES]
    D72.111Lymphocytic Variant Hypereosinophilic Syndrome [LHES]
    D72.119Hypereosinophilic syndrome [HES], unspecified
    J33.0Polyp of nasal cavity
    J33.1Polypoid sinus degeneration
    J33.8Other polyp of sinus
    J33.9Nasal polyp, unspecified
    J40Bronchitis, not specified as acute or chronic
    J41.0Simple chronic bronchitis
    J41.1Mucopurulent chronic bronchitis
    1–10 of 22
    1/3
    Blood eosinophil threshold — Asthma
    Clinical thresholdBaseline blood eosinophil count >= 150 cells/microliter (measured prior to therapy)
    Alternative biomarkersFeNO >= 20 ppb while on high‑dose ICS or daily OCS; sputum eosinophils >= 2% while on high‑dose ICS or daily OCS; or systemic corticosteroid dependence
    Context of useUsed to confirm severe eosinophilic asthma diagnosis per initial approval criteria
    Blood eosinophil threshold — COPD
    Clinical thresholdBaseline blood eosinophil count >= 300 cells/microliter (measured prior to therapy)

    What Providers Must Do

    Prior Authorization

    Prior authorization validity (initial 12 months; renew every 12 months)

    Prior authorization is required; initial authorizations are valid for 12 months (365 days) and may be renewed every 12 months (365 days) thereafter.

    Prior Authorization

    Renewal requires absence of listed concomitant biologic/immunomodulatory agents

    Renewal authorizations require that the member is not receiving any biologic or immunomodulatory agents named in the policy's 'Contraindicated as Concomitant Therapy' list; renewal will not be approved if concurrent use of listed agents is present.

    Prior Authorization

    Renewal: confirm absence of contraindicated concomitant therapies

    Prior authorization renewals must confirm the member is not concurrently receiving any agent explicitly listed as 'Contraindicated as Concomitant Therapy'; confirmation is required at each renewal.

    Background and Drug Information

    Mepolizumab (Nucala) is an anti–interleukin‑5 (IL‑5) monoclonal antibody indicated for eosinophil‑driven diseases. The policy addresses its labeled uses and associated requirements: for severe eosinophilic asthma, dosing and objective confirmation of eosinophilic phenotype and inadequate control on standard therapies are required; other labeled indications addressed in the policy include eosinophilic COPD phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP). The document references the prescribing information and guideline sources for clinical context and requires appropriate diagnostic confirmation and specialist involvement for approval.

    Definitions and Clinical Thresholds

    Severe eosinophilic asthma — definition and thresholds
    DefinitionSevere eosinophilic asthma: asthma with objective eosinophilic biomarker evidence (e.g., baseline blood eosinophils >=150 cells/µL) AND evidence of uncontrolled disease despite controller therapy
    Diagnostic criteria examplesOne of: baseline eosinophils >=150 cells/µL; FeNO >=20 ppb on high‑dose ICS/daily OCS; sputum eosinophils >=2% on high‑dose ICS/daily OCS; or systemic corticosteroid dependence
    Markers of uncontrolled diseaseTwo or more steroid-requiring exacerbations in past 12 months; one or more serious exacerbations requiring hospitalization/ventilation/ED; worsening with steroid taper; or baseline FEV1 <80% predicted
    COPD eosinophilic phenotype — definition and thresholds
    DefinitionCOPD eosinophilic phenotype: COPD confirmed by spirometry (post‑bronchodilator FEV1/FVC < 0.7) with baseline blood eosinophils >= 300 cells/µL

    Policy Revision History

    2026-07-01policy_reviewLatest

    Policy IC-P0260 last reviewed and effective date set; references and appendices updated (Last review 2026-07-01).

    2025-05reference_update

    Updated prescribing information for Nucala (mepolizumab) cited from GlaxoSmithKline LLC, May 2025.

    Policy Summary
    PayerViva Health
    PolicyNucala (mepolizumab) prior authorization and coverage criteria
    Policy CodePolicy IC-P0260
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionPrior authorization is required; initial authorization is valid for 12 months and may be renewed every 12 months thereafter.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling, Dosing Limits, and CodesWhat Providers Must DoBackground and Drug InformationDefinitions and Clinical ThresholdsPolicy Revision History
  1. No contraindications: Member does not have any FDA‑labeled contraindications to the requested agent
  2. Diagnostic confirmationRequires spirometry with post‑bronchodilator FEV1/FVC < 0.7 as part of COPD diagnosis (see COPD criteria)
    Context of useDefines eosinophilic phenotype for COPD initial approval criteria
    Blood eosinophil thresholds — EGPA and HES
    Primary thresholdBaseline blood eosinophil count >= 1000 cells/microliter (measured prior to therapy)
    Alternate threshold for EGPABaseline eosinophils >= 10% on WBC differential (acceptable alternative for EGPA)
    Duration/context for HESFor HES, threshold applies with diagnosis duration >= 6 months and organ evaluation performed
    Dosing frequency
    Standard intervalAdministered once every 4 weeks (q4w)
    Multiple injectionsWhen multiple 100 mg injections required (e.g., 300 mg dose), administer separate injections at least 2 inches apart
    Applies to indicationsDosing interval of every 4 weeks applies across severe eosinophilic asthma, EGPA, HES, CRSwNP, and COPD per labeled dosing
    Prior Authorization

    Contraindicated concomitant therapies must be absent for renewal

    Renewal reviews must verify that the member is not receiving any medications explicitly listed under 'Contraindicated as Concomitant Therapy' with Nucala; absence of those agents is required for renewal.

    Prior Authorization

    Prior authorization/renewal must confirm no contraindicated concomitant therapy

    Prior authorization and renewal decisions must confirm that no concomitant therapy listed as contraindicated is being used; the renewal criteria explicitly reference the enumerated contraindicated concurrent medications.

    Prior Authorization

    Prior authorization required for Nucala — submit Appendix 1 diagnosis code

    Prior authorization is required for Nucala; supporting diagnosis codes submitted for approval should match one of the covered ICD-10 codes listed in Appendix 1.

    Step Therapy

    Controller therapy trials and documented adherence required for asthma/COPD

    For asthma and COPD indications, prior authorization requires documented trials of and adherence to inhaled controller therapies (e.g., ≥3 months of appropriately dosed ICS with 90 days adherence and required LABA/LAMA/LTRA/theophylline as applicable) before approval.

    • Asthma: maximally tolerated inhaled corticosteroid for ≥3 months with 90 days adherence within past 120 days.
    • COPD: ICS plus LAMA/LABA dual therapy for ≥3 months with 90 days adherence within past 120 days.
    Step Therapy

    Step therapy — none specified

    No explicit step therapy sequencing (a formal step-therapy prerequisite pathway) is specified in this policy section.

    Documentation Required

    Required clinical documentation (labs, diagnostics, specialist involvement)

    Required clinical documentation for initial and renewal requests should include baseline laboratory and diagnostic results (for example, blood eosinophil counts, spirometry, CT or nasal endoscopy as appropriate) and specialist documentation when applicable.

    • Baseline blood eosinophil count and other objective diagnostic tests cited in the criteria.
    • Spirometry, CT or nasal endoscopy results when relevant to the indication.
    • Prescriber specialty or documentation of specialist consultation.
    Documentation Required

    Documentation must confirm no listed concomitant agents at renewal

    Renewal documentation must explicitly confirm the member is not concurrently using any medication listed as 'Contraindicated as Concomitant Therapy'; providers must ensure renewal requests do not indicate concurrent use.

    Documentation Required

    Medication history required at renewal — must show absence of contraindicated agents

    Medication history is required for renewal and must show absence of listed contraindicated concomitant biologic or immunomodulatory agents (e.g., adalimumab products, infliximab, benralizumab, baricitinib, and others named in the policy).

    • Include medication history covering recent biologic and immunomodulator use.
    • Document absence of any agent named under 'Contraindicated as Concomitant Therapy.'
    Documentation Required

    Renewal requests must document absence of listed contraindicated concomitant therapies

    Renewal requests should document absence of concomitant use of therapies listed as 'Contraindicated as Concomitant Therapy' with Nucala; this verification should be included in renewal submissions.

    Documentation Required

    Concomitant therapy documentation — verify Nucala not used concurrently with listed agents

    Documentation must support that Nucala is not being used concurrently with any agents enumerated under 'Contraindicated as Concomitant Therapy'; submissions should explicitly address concomitant therapy status.

    Documentation Required

    Required documentation — Nucala NDC/formulation and Appendix 1 diagnosis code

    Providers must document the specific Nucala NDC/formulation administered and include an appropriate covered diagnosis code from Appendix 1 with the authorization request.

    • Include NDC (e.g., 00173-0881-xx, 00173-0892-xx, or 00173-0904-xx) for the product/formulation administered.
    • Include a covered ICD-10 diagnosis code from Appendix 1.
    Denial Risk

    Provider action if initial criteria unmet — risk of denial or need for more documentation

    Requests that do not meet the initial approval criteria (for example, missing required diagnostic confirmation, medication history, or specialist involvement) may be denied or will require additional documentation to be considered.

    Denial Risk

    Contraindicated concomitant therapies may trigger denial of renewal

    Renewal may be denied if the patient is receiving any therapy named in the policy's 'Contraindicated as Concomitant Therapy' list; concurrent use of those agents may trigger denial of renewal.

    Denial Risk

    Contraindicated concomitant therapy may trigger denial

    Renewal may be denied if the member is receiving any agent identified as 'Contraindicated as Concomitant Therapy' with Nucala (mepolizumab); concurrent use is a basis for non‑renewal.

    Denial Risk

    Concomitant contraindicated therapy may trigger denial of coverage/renewal

    Use of listed contraindicated concomitant therapies with Nucala (mepolizumab) may trigger denial of renewal or coverage; providers should avoid concurrent prescribing of listed agents.

    Denial Risk

    Contraindicated concomitant therapy — significant denial risk

    Use of the extensive list of contraindicated concomitant therapies (including multiple biologics, JAK inhibitors, and related agents named in the policy) poses a denial risk for renewal or coverage when used concurrently with Nucala.

    Note

    Prior authorization rationale — NQTL and drug cost considerations

    Prior authorization is applied as a utilization management NQTL; the policy notes prior authorization may be considered due to indication and drug cost per the NQTL checklist.

    Clinical contextRequires history of exacerbations despite maintenance inhaled therapy (e.g., >=2 moderate exacerbations or >=1 severe exacerbation in past 12 months)
    Dosing noteWhen approved, mepolizumab for COPD is dosed 100 mg SC every 4 weeks
    Contraindicated as Concomitant Therapy — explanation
    Purpose of listAgents listed as 'Contraindicated as Concomitant Therapy' are those that must not be used concurrently with Nucala for renewal consideration
    Provider actionRenewal requires documentation that the member is not receiving any named biologic or immunomodulatory agents listed under this heading
    Examples and scopeList includes numerous biologics and small‑molecule immunomodulators (e.g., adalimumab products, infliximab/Inflectra, benralizumab, JAK inhibitors, and others) repeated across the renewal section
    Dosing by indication — labeled dosing summary
    Severe eosinophilic asthma (pediatrics 6–11)40 mg subcutaneously once every 4 weeks
    Severe eosinophilic asthma (adolescents/adults >=12)100 mg subcutaneously once every 4 weeks
    EGPA and HES dosingEGPA: 100 mg SC q4w or 300 mg SC q4w (as three 100 mg injections); HES: 300 mg SC q4w (three 100 mg injections)
    CRSwNP and COPD dosingCRSwNP: 100 mg SC q4w; COPD: 100 mg SC q4w
    Nucala (mepolizumab) — description and prescribing context
    Drug class and targetMepolizumab (Nucala) is a monoclonal antibody (anti‑IL‑5) indicated for certain eosinophilic conditions and severe eosinophilic asthma per prescribing information
    Prescribing contextUsed for severe eosinophilic asthma, eosinophilic COPD phenotype, EGPA, HES, and chronic rhinosinusitis with nasal polyps when criteria are met; dosing and administration per labeled indications
    Administration routeAdministered subcutaneously; when multiple injections required, give injections at least 2 inches apart